TABLE 1.
Baseline characteristics, provoking factors for VTE and laboratory findings in patients with VTE and COVID‐19
| Variable (n = 100) | |
|---|---|
| Patient characteristics | |
| Severe COVID‐19 | 69 (69.0%) |
| Male | 62 (62.0%) |
| Obesity (BMI > 30) | 60 (60%) |
| Smoker | 2 (2.0%) |
| Arterial hypertension | 42 (42.0%) |
| Diabetes | 21 (21.0%) |
| Dyslipidemia | 25 (25.0%) |
| Heart failure | 5 (5.0%) |
| Atrial fibrillation | 3 (3.0%) |
| Ischemic heart disease | 6 (6.0%) |
| Cerebrovascular disease | 4 (4.0%) |
| Peripheral artery disease | 2 (2.0%) |
| Chronic lung disease | 13 (13.0%) |
| Liver disease | 3 (3.0%) |
| Dementia | 6 (6.0%) |
| Antiplatelet therapy | 13 (13.0%) |
| Major bleeding in the last month | 3 (3.0%) |
| Thromboprophylaxis | 69 (69%) |
| Provoking factors for VTE | |
| Active cancer | 7 (7.0%) |
| Recent surgery | 5 (5.0%) |
| Immobilization | 87 (87.0%) |
| <1 wk | 11 (12.6%) |
| 1‐4 wk | 66 (75.9%) |
| 5‐8 wk | 9 (10.3%) |
| >8 wk | 1 (1.1%) |
| Oral contraceptives | 1 (1.0%) |
| Prior VTE | 5 (5.0%) |
| Laboratory findings | |
| Anemia | 47 (47.0%) |
| Thrombocytopenia (<150 000/mm3) | 20 (20.0%) |
| Lymphopenia (<1200/mm3) | 67 (67.0%) |
| Elevated D‐dimer | 99 (99.0%) |
| D‐dimer, median (ng/mL) | 2989 (1846‐8748) |
| Elevated creatinine | 14 (14.0%) |
| Elevated proBNP (only in PE patients) | 57.1% |
Elevated D‐dimer: >250 ng/mL; elevated creatinine: >1.2 mg/dL; elevated pro‐BNP: >500 ng/L.
Abbreviations: BMI, body‐mass index; VTE, venous thromboembolism; BNP, brain natriuretic peptide.